Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | F7 | P08709 | 3/20 | 0.55 |
| ▸ | F3 | P13726 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | FABP3 | P05413 | 2/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722281 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL17743830 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL17744103 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL21197440 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL21197439 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL15317873 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL12186743 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL6037208 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL20603893 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL2640803 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 836 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604533-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | Arbutus Biopharma Corporation (CA) | 2020-02-05 | — | — | EP | claimed |
| US-9895448-B2 | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-02-20 | — | — | US | claimed |
| US-20160367687-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-22 | — | — | US | claimed |
| US-8575123-B2 | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2013-11-05 | — | — | US | claimed |
| JP-2011518784-A | — | — | 2011-06-30 | — | — | JP | claimed |
| US-20110123520-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | claimed |
| EP-2274425-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | Alnylam Pharmaceuticals Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| WO-2009126933-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125339-A1 | IONIZABLE CATIONIC LIPIDS | TRANSLATE BIO INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12590305-B2 | Complement component C5 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4712979-A1 | COMPOUNDS AND ADJUVANT FORMULATIONS USEFUL IN PNEUMOCOCCAL VACCINES | Merck Sharp & Dohme LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2010042877-A1 | IMPROVED AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009132131-A1 | AMINO LIPID BASED IMPROVED LIPID FORMULATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132131-A1 | AMINO LIPID BASED IMPROVED LIPID FORMULATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009126933-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126933-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009086558-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | LDLR, NR1H3, NR1H2 | FFAR1 261/4885FFAR4 810/4885ALDH1A1 2418/4885 |
| US-12590305-B2 | Complement component C5 iRNA compositions and methods of use thereof | UPF1, C5, NSUN2 | FFAR1 4417/4885FFAR4 4489/4885ALDH1A1 2799/4885 |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | RNASEL, NSUN2, ADAR | FFAR1 4797/4885FFAR4 4811/4885ALDH1A1 4415/4885 |
| US-20160367687-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, LNPEP, BST2 | FFAR1 3871/4885FFAR4 3987/4885ALDH1A1 4541/4885 |
| US-20110123520-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, LNPEP, BST2 | FFAR1 3871/4885FFAR4 3987/4885ALDH1A1 4541/4885 |
| US-20260125339-A1 | IONIZABLE CATIONIC LIPIDS | NPC1L1, PHOSPHO1, NPC1 | FFAR1 164/4885FFAR4 231/4885ALDH1A1 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.